ASCO
Refine search
Biotechnology
Eagerly-anticipated data from an ongoing Phase I/II trial into epacadostat in combination with Keytruda have been released, as the annual meeting of the American Society of Clinical Oncology continues in Chicago. 4 June 2017
Biotechnology
Bristol-Myers Squibb has announced data from a Phase II trial evaluating Opdivo as a monotherapy and in combination with Yervoy, in colorectal cancer (CRC). 4 June 2017
Biotechnology
Top-line data from Janssen’s eagerly-awaited clinical trial into Zytiga in combination with the standard of care for advanced prostate cancer have been released. 4 June 2017
Biotechnology
Novartis announced today updated findings from the Phase III MONALEESA-2 study that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. 2 June 2017
Pharmaceutical
In our latest ASCO-themed expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, discusses why the oncology sector is seeing increased M&A activity and offers advice to buyers and sellers on how to maximize opportunities in the market and complete deals on the most favorable terms. 2 June 2017
Pharmaceutical
Phase III data on Anglo-Swedish pharma major AstraZeneca’s of Lynparza (olaparib) 300mg twice-daily tablet maintenance treatment shows that quality of life (QoL) is sustained alongside improved progression-free survival (PFS) in women with germline BRCA-mutated (gBRCAm), platinum-sensitive, relapsed serous ovarian cancer. 2 June 2017
Biosimilars
With data on so many innovative but expensive new oncology treatments being presented at ASCO 2017, it is a crucial period for biosimilars of three of the world's biggest-selling cancer drugs to deliver their promised savings, and this feature looks at the progress of these copycat biologics in reaching markets and patients. 1 June 2017
Biotechnology
Data from a pilot study of cancer candidate CTL119, in combination with ibrutinib, will soon be made available by Basel-based Novartis. 31 May 2017
Pharmaceutical
Germany’s Merck KGaA has not appeared near the summit of any rankings on top pharma companies by oncology revenue in recent years, with earnings from its sole cancer product Erbitux (cetuximab) dropping to below $1 billion in 2016. 31 May 2017
Biotechnology
Speaking with The Pharma Letter ahead of the upcoming annual meeting of the American Society of Clinical Oncology, Michael Pehl says that: “We are really excited about the event - we have a really broad range of clinical data.” 26 May 2017
Biotechnology
Colorectal cancer (CRC) exemplifies the steady progress we’ve made in cancer prevention and treatment, writes Dr Samuel Klempner, director of precision medicine at The Angeles Clinic & Research Institute, in the first oncology-themed Expert View piece being published around this year's ASCO Annual Meeting. 25 May 2017
Pharmaceutical
In the run up to the annual meeting of the American Society of Clinical Oncology, we present the first of three analyses focusing on the state of cancer research and care. This week, our correspondent Simon Wentworth reviews progress in the much-anticipated field of precision oncology. 23 May 2017
Pharmaceutical
As the industry’s major players begin to release their curtain raisers, presentation schedules and abstracts ahead of ASCO’s annual meeting, it’s possible to gain some insight into the likely key themes at this year’s event. 19 May 2017
Biotechnology
California-headquartered biotech major Amgen will provide a public update on several key Phase III programs at next month’s annual meeting of the American Society of Clinical Oncology. 19 May 2017
Pharmaceutical
German drugmaker Merck KGaA and US pharma giant Pfizer have promised that 13 abstracts on avelumab across seven hard-to-treat cancers will be presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. 19 May 2017
Pharmaceutical
No fewer than 20 medicines from Swiss pharma giant Roche will be included in more than 190 abstracts being presented at next month’s 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. 12 May 2017
Pharmaceutical
The Pharma Letter's Katie Osborne sums up some of the most exciting research and innovative new cancer treatments presented at this year's annual meeting of the American Society of Clinical Oncology. 12 June 2016
Biotechnology
Recent data from the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting have shown that rovalpituzumab tesirine (Rova-T), AbbVie’s (NYSE: ABBV) antibody-drug conjugate (ADC) to treat recurrent/refractory small cell lung cancer (SCLC), represents a promising new approach, as it is the first biomarker-directed therapy for treating the disease, an aggressive form of lung cancer that accounts for around 15% of all lung cancers. 11 June 2016
Biotechnology
Merck & Co has published updated findings from its Keynote-012 trials for its head and neck cancer drug Keytruda (pembrolizumab) at the American Society of Clinical Oncologists (ASCO) 2016 conference. 10 June 2016
Pharmaceutical
A pilot study has shown the huge differences in retail prices of cancer drugs in different countries, and highlighted the burden the cost puts on patients in many parts of the world. 7 June 2016
Biotechnology
Taiwanese biotech PharmaEssentia is preparing to seek an expanded US label for its long-acting interferon Besremi (ropeginterferon alfa-2b) following new late-stage data that show the therapy outperforms anagrelide in treating essential thrombocythaemia (ET) after hydroxyurea failure. 3 June 2025
Pharmaceutical
Detailed results from the Phase III OASIS-4 study have found that Bayer’s elinzanetant showed a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms (VMS, also known as hot flushes) from baseline to week four and 12 compared to placebo, in women taking endocrine therapy to prevent hormone receptor (HR+) breast cancer. 2 June 2025
Pharmaceutical
Positive results from the SERENA-6 Phase III trial have shown that AstraZeneca’s camizestrant alongside a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) led to a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS). 2 June 2025
Biotechnology
The Alliance for Clinical Trials in Oncology has announced results from ATOMIC, a Phase III trial evaluating standard chemotherapy alone or combined with Roche’s Tecentriq (atezolizumab) in patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). 2 June 2025
Biotechnology
With ASCO 2025 drawing toward its close in Chicago, Amsterdam-based biotech Avidicure is entering the spotlight with its first public data on a new class of cancer immunotherapies. The company’s lead program, AVC-S-101, is designed to target TROP2 in non-small cell lung cancer (NSCLC) and other solid tumors. 2 June 2025
Biotechnology
US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 inhibitor Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. 2 June 2025
Biotechnology
AstraZeneca has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its immunotherapy Imfinzi (durvalumab) to significantly delay disease progression in patients with early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers. 2 June 2025
Pharmaceutical
Arcus Biosciences is setting the stage for a high-stakes Phase III showdown in kidney cancer, after early results showed that nearly half of patients treated with its experimental therapy had a confirmed response. 2 June 2025
Pharmaceutical
US drugmaker Protagonist Therapeutics and Japan’s Takeda Pharma announced detailed results from the Phase III, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. 2 June 2025
Pharmaceutical
Arvinas and Pfizer today announced detailed results from the Phase III VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. 2 June 2025
Pharmaceutical
US pharma giant Pfizer on Saturday announced statistically-significant and clinically-meaningful survival results from the Phase III BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. 2 June 2025
Biotechnology
Daiichi Sankyo and AstraZeneca have released detailed Phase III results that could help position their HER2-targeting drug Enhertu (trastuzumab deruxtecan) as the second-line standard of care for advanced gastric cancer. 2 June 2025
Biotechnology
In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate IMNN-001. We interviewed president and chief executive Stacy Lindborg on the long path to this moment—and what may lie ahead in the evolving ovarian cancer treatment landscape. 28 May 2025
Pharmaceutical
Germany’s Merck KGaA today announced the presentation of detailed positive results from Part 1 of the global Phase III MANEUVER trial evaluating pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics, in the treatment of patients with tenosynovial giant cell tumor (TGCT). 28 May 2025
Biotechnology
French biotech ImCheck Therapeutics is preparing to showcase encouraging interim results for its investigational monoclonal antibody ICT01 at the 2025 ASCO Annual Meeting, highlighting the compound’s potential to improve outcomes in acute myeloid leukemia (AML) patients not eligible for intensive chemotherapy. 27 May 2025
Pharmaceutical
Verastem Oncology has unveiled updated early-stage data from its RAMP 205 trial in metastatic pancreatic cancer, bolstering its efforts to broaden use of its dual-drug regimen, Avmapki Fakzynja Co-Pack, beyond its recently approved indication in a rare form of ovarian cancer. 23 May 2025
Pharmaceutical
Japanese drugmaker Astellas and US pharma giant Pfizer have announced longer-term follow-up results from an open-label extension of the Phase III ARCHES study. 23 May 2025
Biotechnology
Among the companies displaying the strength of Chinese research in oncology at the 2025 ASCO Annual Meeting will be Hutchmed. 23 May 2025
Biotechnology
Swiss pharma major Roche has reported updated results from its Phase III STARGLO trial, showing that a fixed-duration regimen of Columvi (glofitamab) combined with gemcitabine and oxaliplatin (GemOx) continues to deliver a notable survival benefit for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). 23 May 2025
Pharmaceutical
The oncology community’s biggest gathering returns to Chicago from May 30 to June 3, and all signs suggest the 2025 ASCO Annual Meeting will be a watershed moment. 23 May 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze